CSPC Pharma's SYH2051 Combined with Irinotecan Liposome Enters Phase Ib/II Clinical Trial for Advanced Solid Tumors, First Site Launched in China

Stock News
昨天

CSPC PHARMA (01093) has announced that the Phase Ib/II clinical trial of its developed SYH2051 combined with irinotecan liposome for the treatment of advanced solid tumors has officially been initiated at the first research site in China.

The product is a highly selective inhibitor of ataxia-telangiectasia mutated (ATM) protein kinase, registered as a Class 1 chemical drug. It selectively inhibits the activity of ATM kinase, a core component of the cellular DNA damage repair system, thereby preventing DNA damage repair in tumor cells.

The clinical trial now launched is a multicenter, open-label Phase Ib/II study designed to enroll patients with advanced solid tumors, aiming to evaluate the safety and efficacy of the product in combination with irinotecan liposome.

Currently, participant recruitment and screening for this clinical trial are being actively advanced.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10